BIOMARKER DISCOVERY & BIOMARKERS RESEARCH
Thomson Reuters believes that biomarkers will become one of the major driving forces of pharmaceutical research and drug development in the coming years.
Thomson Reuters IntegritySM combines its unique biomarker database with related drugs, targets and genes to give researchers a powerful tool to ensure you make informed decisions as you strive to improve cost efficiency, predict and minimise risk and avoid late stage attrition.
Continually updated the Integrity Biomarkers Module draws on data from literature, patents, conferences, medical meeting to support biomarker research at every stage of drug R&D including: target identification; proof of mechanism; proof of concept; treatment/safety monitoring; and outcome measurement.
Therapy areas include oncology, cardiovascular disease, diabetes and other endocrine disease, immunology, respiratory diseases, neurological disorders, pain, infectious disease and musculoskeletal and connective tissue disorders.
Latest BIOMARKER News
THOMSON REUTERS ARTICLES:
- Drug Discovery, Personalized Medicine and Thomson Reuters
- The problem with cancer
- Disease detectives
Listen to renowned Oncology expert Dr Jeffrey Ross discuss the potential of biomarkers to revolutionize drug research and development and patient treatment.
BIOMARKER WHITE PAPERS:The Promise of Imaging Biomarkers
Get a snapshot of the imaging biomarkers at use and discover what leading experts consider the key technical and commercialization challenges.
Biomarkers: An indispensible addition to the drug development toolkit
Explore the role of biomarkers as evaluative tools in improving clinical research and the challenges this presents.
Establishing the standards in biomarkers research
The pharmaceutical industry is already beginning to rely on biomarker information and it importance to the future of drug discovery and development.
The Thomson Reuters biomarker database has a strong focus on cancer biomarkers. Click here to link through to more information and resources.